Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.
Julia FoldiAdriana M KahnAndrea L M SilberTao QingEmily ReisenbichlerNeal FischbachJustin PersicoKerin AdelsonAnamika KatochAnees ChagparTristen ParkAdam BlanchardKim R M BlenmanDavid L RimmLajos PusztaiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
pCR rates, 3-year OS and EFS after neoadjuvant immunotherapy and chemotherapy were similar in AA and non-AA patients. Toxicities, including the frequency of irAEs, were also similar.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- early stage
- clinical trial
- rectal cancer
- end stage renal disease
- lymph node
- sentinel lymph node
- ejection fraction
- squamous cell carcinoma
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- patient reported outcomes
- study protocol
- phase ii
- patient reported